MedTrace Logo

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

NCT05888857 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-08-13

No results posted yet for this study

Summary

Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

MEDI5752

A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • AstraZeneca

    collaborator INDUSTRY

  • Institut Bergonié

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-03-31
Completion
2028-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05888857 on ClinicalTrials.gov